Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir

Table 1 Demographical and clinical characteristics of chronic hepatitis C patients

Sex (F/M)	Age (yr)	BMI (kg/m2)	Fibroscan index	Treatment-naïve /experienced	ALT/AST(U/L)-baseline	ALT/AST(U/L)-week 2	Log HCV RNA	Response to sofosbuvir/ledipasvir
F	27	18.71	3.8	N	25/25	10/19	6.16	SVR24
M	62	15.85	6.5	N	55/47	24/23	6.09	SVR24
F	30	20.07	5.9	N	18/20	10/19	6.38	SVR24
F	53	20.10	3.9	N	11/25	6/19	6.98	SVR24
M	25	24.39	6.1	N	43/22	23/18	4.60	SVR24
F	27	19.38	7.9	N	20/20	11/22	6.87	SVR24
F	29	26.67	6.4	N	32/24	16/14	5.90	SVR24
M	24	29.33	7.6	E	85/75	10/16	6.45	SVR24
M	63	25.10	4.8	E	50/32	31/23	6.51	SVR24
M	55	23.62	4.5	E	34/30	24/20	6.56	SVR24
F	57	22.31	4.7	E	20/26	15/20	6.76	SVR24
F	63	26.75	4.3	E	27/29	11/19	6.76	SVR24
M	25	26.53	6.0	E	30/23	11/22	6.60	SVR24

F: Female; M: Male; N: Treatment-naïve; E: Treatment-experienced; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HCV: Hepatitis C virus; SVR: Sustained virological response.